Latent Tuberculosis Infection Clinical Trial
Official title:
Performance Evaluation of the VIDAS TB-IGRA Assay.
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection. This study is designed to assess (1) the sensitivity of this assay, (2) its percent agreement with other diagnostic tests, (3) its measurement precision , and (4) any potential interference of the presence of other non-tuberculosis mycobacterial bacterial infections with this assay.
Tuberculosis (TB) infection is one of the top 10 causes of death in the world and the leading cause of death due to a single infectious agent. Millions of people are infected with TB each year which can pose significant economic and health care burdens on the global population. TB can infected the lungs (pulmonary TB) or other organs such as the brain, and kidneys (extra-pulmonary TB). When a person with pulmonary TB coughs or sneezes, water droplets containing M. tuberculosis are expelled into the air. Persons can become infected with TB when they inhale air containing these water droplets, however, not everyone infected with Mycobacterium tuberculosis (Mtb) becomes ill. Therefore two TB-related conditions exist: latent TB infection (LTBI) and TB disease. People with latent TB infection are not ill and do not present TB symptoms or have TB disease. The only sign of TB infection is a positive reaction to the tuberculin skin test or TB blood tests such as IGRA tests. People with latent TB infection are not contagious and cannot spread TB infection to others. Identification and treatment of LTBI can substantially reduce the risk of developing active disease. However, there is no diagnostic gold standard for LTBI. Two types of test are currently available for the identification of LTBI: the tuberculin skin test (TST) and the TB Interferon Gamma (IFN-γ) Release Assay (TB-IGRA). Evidence suggests that both TST and TB-IGRA are acceptable but not perfect because they detect indirect markers of Mtb exposure and indicate a cellular immune response to M. tuberculosis. TB-IGRAs have a number of advantages compared to TST which promote their progressive adoption in the clinical practice and in guidelines. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04094012 -
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
|
Phase 3 | |
Completed |
NCT01582711 -
Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
|
Phase 3 | |
Recruiting |
NCT06033807 -
Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
|
||
Completed |
NCT01622140 -
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
|
||
Completed |
NCT00557765 -
Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area
|
N/A | |
Completed |
NCT00463086 -
Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons
|
N/A | |
Active, not recruiting |
NCT01398618 -
Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)
|
Phase 3 | |
Recruiting |
NCT00905970 -
Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection
|
N/A | |
Recruiting |
NCT00449345 -
Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis
|
N/A | |
Completed |
NCT02641106 -
VDOT for Monitoring Adherence to LTBI Treatment
|
N/A | |
Completed |
NCT00804713 -
Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits
|
N/A | |
Completed |
NCT01136161 -
Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection
|
Phase 2 | |
Recruiting |
NCT03312647 -
Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection
|
N/A | |
Completed |
NCT02810678 -
Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment
|
N/A | |
Completed |
NCT01223534 -
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
|
Phase 4 | |
Withdrawn |
NCT00558480 -
Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis
|
N/A | |
Recruiting |
NCT00692809 -
Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection
|
N/A | |
Completed |
NCT03702049 -
Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV
|
N/A | |
Terminated |
NCT01761201 -
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
|
Phase 3 | |
Completed |
NCT01608685 -
Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients
|
N/A |